BBR Partners LLC Sells 63 Shares of Eli Lilly and Company (NYSE:LLY)

BBR Partners LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,596 shares of the company’s stock after selling 63 shares during the quarter. BBR Partners LLC’s holdings in Eli Lilly and Company were worth $1,414,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. First Commonwealth Financial Corp PA boosted its stake in shares of Eli Lilly and Company by 0.8% during the third quarter. First Commonwealth Financial Corp PA now owns 2,056 shares of the company’s stock valued at $1,821,000 after purchasing an additional 16 shares during the period. RPg Family Wealth Advisory LLC purchased a new position in shares of Eli Lilly and Company in the third quarter valued at about $93,000. CreativeOne Wealth LLC raised its stake in shares of Eli Lilly and Company by 65.3% during the third quarter. CreativeOne Wealth LLC now owns 8,416 shares of the company’s stock valued at $7,456,000 after acquiring an additional 3,326 shares during the last quarter. BNP Paribas boosted its holdings in shares of Eli Lilly and Company by 38.8% during the third quarter. BNP Paribas now owns 40,520 shares of the company’s stock worth $35,772,000 after purchasing an additional 11,327 shares during the period. Finally, Blueshift Asset Management LLC bought a new stake in shares of Eli Lilly and Company in the third quarter worth about $881,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.1 %

Shares of LLY stock opened at $788.35 on Thursday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The stock has a market capitalization of $748.40 billion, a P/E ratio of 85.23, a P/E/G ratio of 2.86 and a beta of 0.43. The firm’s 50 day moving average is $856.96 and its 200 day moving average is $869.83.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. Research analysts expect that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is currently 56.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Barclays lowered their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.